125 related articles for article (PubMed ID: 32950635)
41. [Effects of chemotherapy combined with Chinese herbal medicine Kangliu Zengxiao decoction on tumor markers of patients with advanced non-small-cell lung cancer: a randomized, controlled trial].
Yan GY; Xu ZY; Deng HB; Wan ZY; Zhang L; Zhu JY
Zhong Xi Yi Jie He Xue Bao; 2011 May; 9(5):525-30. PubMed ID: 21565138
[TBL] [Abstract][Full Text] [Related]
42. [Correlation of CD4
Li SJ; Wu YX; Chen HL; Liu ML; Wu AB; Yang ZX
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(9):1215-1220. PubMed ID: 27687653
[TBL] [Abstract][Full Text] [Related]
43. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
44. Biomarkers along the continuum of care in lung cancer.
Holdenrieder S
Scand J Clin Lab Invest Suppl; 2016; 245():S40-5. PubMed ID: 27542002
[TBL] [Abstract][Full Text] [Related]
45. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
46. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
[TBL] [Abstract][Full Text] [Related]
47. [Tumor marker in primary lung cancer].
Sugio K; Sugaya M; Hanagiri T; Yasumoto K
J UOEH; 2004 Dec; 26(4):473-9. PubMed ID: 15624359
[TBL] [Abstract][Full Text] [Related]
48. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
49. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
50. Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
Sone K; Oguri T; Ito K; Kitamura Y; Inoue Y; Takeuchi A; Fukuda S; Takakuwa O; Maeno K; Asano T; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
Anticancer Res; 2017 Sep; 37(9):5125-5131. PubMed ID: 28870944
[TBL] [Abstract][Full Text] [Related]
51. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
52. [The clinical signifinace of CEA, Cyfra21-1 and SCC in laryngeal carcinoma's clinicopathological parameters].
Rao LH; Zhang L; Tian L; Yan JR; Xiang XY; Yu FB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Aug; 31(15):1182-1186. PubMed ID: 29798354
[No Abstract] [Full Text] [Related]
53. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
54. [Significance of serum neuron-specific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer].
Chen Y; Peng W; Huang Y; Chen J; Su G; Jiang C; Xiao Y
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):508-11. PubMed ID: 26463326
[TBL] [Abstract][Full Text] [Related]
55. Downregulation of serum exosomal miR-216b predicts unfavorable prognosis in patients with non-small cell lung cancer.
Liu W; Liu J; Zhang Q; Wei L
Cancer Biomark; 2020; 27(1):113-120. PubMed ID: 31771047
[TBL] [Abstract][Full Text] [Related]
56. Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients.
Szymanowska-Narloch A; Jassem E; Skrzypski M; Muley T; Meister M; Dienemann H; Taron M; Rosell R; Rzepko R; Jarząb M; Marjański T; Pawłowski R; Rzyman W; Jassem J
Adv Med Sci; 2013; 58(2):196-206. PubMed ID: 24451080
[TBL] [Abstract][Full Text] [Related]
57. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
[TBL] [Abstract][Full Text] [Related]
59. Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers.
Woenckhaus M; Klein-Hitpass L; Grepmeier U; Merk J; Pfeifer M; Wild P; Bettstetter M; Wuensch P; Blaszyk H; Hartmann A; Hofstaedter F; Dietmaier W
J Pathol; 2006 Oct; 210(2):192-204. PubMed ID: 16915569
[TBL] [Abstract][Full Text] [Related]
60. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
